Abstract
Obesity in human was found mainly due to the poor transportation of leptin through brain-blood barrier (BBB), called as leptin resistance. To produce a leptin capable of penetrating BBB, we have added Tat-PTD(9) to the C terminal of leptin to construct a fusion protein. The fusion Tat-leptin and native leptin genes were synthesized by single-step insertion of a polymerase chain reaction and expressed in Escherichia coli BL21 (RossetaTM ). The expressing products were purified and renatured by Ni-NTA affinity chromatography, and identified by the molecular size in SDS-PAGE gel and by its immunoreactivity to specific antibody with Western-blotting assay. To bio-functionally evaluate the fusion protein, Balb/c mice fed with high-fat diet (HFD) were given Tat-leptin, leptin or saline for 19 days. The immunohistochemical staining showed the increases in positive stains for the leptin in the region of hypothalamus of the HFD mice with either Tat-leptin or leptin as compared to saline group, but the staining intensity and frequency in the group with Tat-leptin were stronger and higher than those in the group with leptin. Furthermore, the most efficiency in preventing the body-weight gain caused by HFD was found in Tat-leptin group among these three groups. These results suggest that Tat-modified leptin may become a great potential candidate for the prevention or therapy of obese patients.
Key words
Tat - leptin - obesity - blood-brain barrier - body weight
References
1
Arch JR, Stock MJ, Trayhurn P.
Leptin resistance in obese humans: does it exist and what does it mean?.
Int J Obes Relat Metab Disord.
1998;
22
1159-1163
2
Cao G, Pei W, Ge H. et al .
In vivo delivery of a Bcl-xL fusion protein containing the TAT protein transduction domain protects against ischemic brain injury and neuronal apoptosis.
J Neurosci.
2002;
22
5423-5431
3
Caro JF, Kolaczynski JW, Nyce MR. et al .
Decreased cerebrospinal-fluid/serum leptin ratio in obesity: a possible mechanism for leptin resistance.
Lancet.
1996;
348
159-161
4
Considine RV, Considine EL, Williams CJ. et al .
Evidence against either a premature stop codon or the absence of obese gene mRNA in human obesity.
J Clin Invest.
1995;
95
2986-2988
5
Considine RV, Considine EL, Williams CJ. et al .
The hypothalamic leptin receptor in humans: identification of incidental sequence polymorphisms and absence of the db/db mouse and fa/fa rat mutations.
Diabetes.
1996a;
45
992-994
6
Considine RV, Considine EL, Williams CJ. et al .
Mutation screening and identification of a sequence variation in the human ob gene coding region.
Biochem Biophys Res Commun.
1996b;
220
735-739
7
Dietz GP, Valbuena PC, Dietz B. et al .
Application of a blood-brain-barrier-penetrating form of GDNF in a mouse model for Parkinson's disease.
Brain Res.
2006;
1082
61-66
8
El-Hage N, Wu G, Ambati J. et al .
CCR2 mediates increases in glial activation caused by exposure to HIV-1 Tat and opiates.
J Neuroimmunol.
2006;
178
9-16
9
El-Haschimi K, Lehnert H.
Leptin resistance – or why leptin fails to work in obesity.
Exp Clin Endocrinol Diabetes.
2003;
111
2-7
10
Foged C, Nielsen HM.
Cell-penetrating peptides for drug delivery across membrane barriers.
Expert Opin Drug Deliv.
2008;
5
105-117
11
Gump JM, Dowdy SF.
TAT transduction: the molecular mechanism and therapeutic prospects.
Trends Mol Med.
2007;
13
443-448
12
Halaas JL, Gajiwala KS, Maffei M. et al .
Weight-reducing effects of the plasma protein encoded by the obese gene.
Science.
1995;
269
543-546
13
Hamilton BS, Paglia D, Kwan AY. et al .
Increased obese mRNA expression in omental fat cells from massively obese humans.
Nat Med.
1995;
1
953-956
14
Huq I, Ping YH, Tamilarasu N. et al .
Controlling human immunodeficiency virus type 1 gene expression by unnatural peptides.
Biochemistry.
1999;
38
5172-5177
15
Jeong KJ, Lee SY.
High-level production of human leptin by fed-batch cultivation of recombinant Escherichia coli and its purification.
Appl Environ Microbiol.
1999;
65
3027-3032
16
Kim D, Jeon C, Kim JH. et al .
Cytoplasmic transduction peptide (CTP): new approach for the delivery of biomolecules into cytoplasm in vitro and in vivo.
Exp Cell Res.
2006;
312
1277-1288
17
Klein S, Coppack SW, Mohamed-Ali V. et al .
Adipose tissue leptin production and plasma leptin kinetics in humans.
Diabetes.
1996;
45
984-987
18
Lindgren M, Hallbrink M, Prochiantz A. et al .
Cell-penetrating peptides.
Trends Pharmacol Sci.
2000;
21
99-103
19
Maffei M, Halaas J, Ravussin E. et al .
Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects.
Nat Med.
1995;
1
1155-1161
20
Nagayoshi C, Ishibashi M, Kita Y. et al .
Expression, refolding and characterization of human brain serine racemase in Escherichia coli with N-terminal His-tag.
Protein Pept Lett.
2005;
12
487-490
21
Oliveros H, Villamor E.
Obesity and mortality in critically ill adults: a systematic review and meta-analysis.
Obesity (Silver Spring).
2008;
16
515-521
22
Pelleymounter MA, Cullen MJ, Baker MB. et al .
Effects of the obese gene product on body weight regulation in ob/ob mice.
Science.
1995;
269
540-543
23
Reece EA.
Obesity, diabetes, and links to congenital defects: a review of the evidence and recommendations for intervention.
J Matern Fetal Neonatal Med.
2008;
21
173-180
24
Schwartz MW, Peskind E, Raskind M. et al .
Cerebrospinal fluid leptin levels: relationship to plasma levels and to adiposity in humans.
Nat Med.
1996;
2
589-593
25
Segal KR, Landt M, Klein S.
Relationship between insulin sensitivity and plasma leptin concentration in lean and obese men.
Diabetes.
1996;
45
988-991
26
Sengoku T, Bondada V, Hassane D. et al .
Tat-calpastatin fusion proteins transduce primary rat cortical neurons but do not inhibit cellular calpain activity.
Exp Neurol.
2004;
188
161-170
27
Shimizu H, Oh IS, Okada S. et al .
Leptin resistance and obesity.
Endocr J.
2007;
54
17-26
28
Steinberg GR, Dyck DJ, Calles-Escandon J. et al .
Chronic leptin administration decreases fatty acid uptake and fatty acid transporters in rat skeletal muscle.
J Biol Chem.
2002;
277
8854-8860
29
Terpe K.
Overview of bacterial expression systems for heterologous protein production: from molecular and biochemical fundamentals to commercial systems.
Appl Microbiol Biotechnol.
2006;
72
211-222
30
Trogdon JG, Finkelstein EA, Hylands T. et al .
Indirect costs of obesity: a review of the current literature.
Obes Rev.
2008;
31
Van Heek M, Compton DS, France CF. et al .
Diet-induced obese mice develop peripheral, but not central, resistance to leptin.
J Clin Invest.
1997;
99
385-390
32
Weigle DS, Bukowski TR, Foster DC. et al .
Recombinant ob protein reduces feeding and body weight in the ob/ob mouse.
J Clin Invest.
1995;
96
2065-2070
33
Woodside B, Abizaid A, Jafferali S.
Effect of acute food deprivation on lactational infertility in rats is reduced by leptin administration.
Am J Physiol.
1998;
274
R1653-1658
34
Yin W, Cao G, Johnnides MJ. et al .
TAT-mediated delivery of Bcl-xL protein is neuroprotective against neonatal hypoxic-ischemic brain injury via inhibition of caspases and AIF.
Neurobiol Dis.
2006;
21
358-371
35
Zhang Y, Proenca R, Maffei M. et al .
Positional cloning of the mouse obese gene and its human homologue.
Nature.
1994;
372
425-432
1 * Equal contribution to this work
Correspondence
Dr. X. Li
The Chinese-American Research
Institute for Diabetic Complications
Chashan College Park
Wenzhou
Zhejiang Province
325035 China
Telefon: +011/86/136 76 70 17 96
Fax: +011/86/577 86 69 93 50
eMail: xiaokunli@163.net
Dr. L. Cai
511 South Floyd Street
MDR 533
Louisville
KY 40202
USA
Telefon: +502/852/22 14
Fax: +502/852/56 34
eMail: L0cai001@louisville.edu